Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02123017 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02123017: Completed Phase 2 study, sponsored by Cumberland Pharmaceuticals.
NCT02123017 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02123017, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with escalating doses of lactulose to be used as a preparation for colonoscopy.
Primary Outcome
Efficacy assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Preparation Scale (BBPS). 9 is the maximum score, representing an fully cleansed colon; 0 is the minimal score, representing a colon with no cleaning.
Interventions
- DRUG 90 grams of Crystalline Lactulose
- DRUG 135 grams of Crystalline Lactulose
- DRUG 180 grams of Crystalline Lactulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT02123017 record still lists
NCT02123017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which 90 grams of Crystalline Lactulose is the first listed.
NCT02123017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02123017 about?
NCT02123017 is a clinical study titled "Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy". The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with escalating doses of lactulose to be used as a preparation for colonoscopy.
What is the current status of trial NCT02123017?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-04. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02123017?
The interventions under investigation include: 90 grams of Crystalline Lactulose (DRUG), 135 grams of Crystalline Lactulose (DRUG), 180 grams of Crystalline Lactulose (DRUG).
Who is sponsoring clinical trial NCT02123017?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02123017's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia